ArticlePLoS pathogens2026

Topical formulation of repurposed FDA-approved compounds inhibits Pseudomonas aeruginosa ExoU and improves corneal infection outcomes.

Daniel M Foulkes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.